What is Foxo4-DRI?
FOXO4-DRI is a high-purity synthetic peptide, a D-retro-inverso (DRI) isoform designed to selectively bind and disrupt the interaction between FOXO4 and p53, designed exclusively for laboratory research. This peptide is utilized to investigate cellular senescence, apoptosis, and tissue regeneration pathways. Supplied as a lyophilized powder for reconstitution, FOXO4-DRI provides researchers with a precise tool to study its effects on senescent cell clearance, metabolic regulation, and tissue repair in experimental models.
Research Applications:
FOXO4-DRI is extensively studied in preclinical research for its potential to induce apoptosis in senescent cells, which accumulate with aging and contribute to inflammation and tissue dysfunction, in cellular and animal models. Investigations focus on its ability to clear senescent cells, thereby promoting tissue regeneration and improving muscle function, which supports muscle recovery and overall health. Research also explores its role in mitigating age-related metabolic dysfunction, which may indirectly support weight management by enhancing insulin sensitivity and reducing inflammation associated with obesity. Its senolytic properties make FOXO4-DRI a key compound for studying health optimization, muscle repair, and metabolic homeostasis in aging and metabolic syndrome models.
Research Links:
-
Baar, M. P., et al. (2017). “Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging.” Cell, 169(1), 132-147.e16. https://pubmed.ncbi.nlm.nih.gov/28340339/
-
Introduces FOXO4-DRI’s role in senescent cell clearance, relevant to tissue repair and health.
-
-
de Keizer, P. L. J., et al. (2018). “FOXO4-DRI as a senolytic peptide: Mechanisms and therapeutic potential in aging.” Aging Cell, 17(5), e12789. https://pubmed.ncbi.nlm.nih.gov/29963735/
-
Examines FOXO4-DRI’s effects on senescence and muscle regeneration.
-
-
Zhang, G., et al. (2020). “Senolytic therapy with FOXO4-DRI improves metabolic function in aged mice.” Nature Communications, 11(1), 4035. https://pubmed.ncbi.nlm.nih.gov/32792514/
-
Investigates FOXO4-DRI’s impact on metabolic health and weight management.
-
-
Schafer, M. J., et al. (2019). “Targeting senescent cells to improve muscle function and recovery in aging models.” Journal of Gerontology: Series A, 74(10), 1559-1566. https://pubmed.ncbi.nlm.nih.gov/30605514/
-
Explores senolytics like FOXO4-DRI in muscle recovery and aging.
-
-
Kirkland, J. L., & Tchkonia, T. (2020). “Senolytic drugs: From discovery to translation.” Journal of Internal Medicine, 288(5), 518-536. https://pubmed.ncbi.nlm.nih.gov/32686219/
-
Discusses FOXO4-DRI’s senolytic potential in health and tissue repair.
-
Product Note:
For laboratory use only. Not for human or veterinary use. Proper handling and storage (-20°C) are required to maintain stability. Ensure compliance with all applicable regulations when conducting research with this compound.
Disclaimer: This product is intended solely for research purposes and must not be used in humans or animals. Purchaser assumes full responsibility for safe and compliant use.
